Á lódáil...
Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
This year the medical community was pleasantly surprised by the results of the first large outcome trial that primarily examined the renal effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (CANA) in subjects with diabetes and impaired kidney function. The Evaluation of th...
Na minha lista:
| Foilsithe in: | Nephrol Dial Transplant |
|---|---|
| Main Authors: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Oxford University Press
2020
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6993196/ https://ncbi.nlm.nih.gov/pubmed/32003836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfz264 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|